Calico Life Sciences, Alphabet's aging-focused biotech, has entered a licensing agreement valued at up to $596 million for clinical-stage monoclonal antibody programs targeting interleukin-11 developed by China-based Mabwell Bioscience. Calico obtained exclusive global rights outside greater China to develop and commercialize these IL-11 directed therapies, including the candidate 9MW3811, which is currently in Phase 1 trials for idiopathic pulmonary fibrosis in China and Australia. The deal aligns with Calico's mission to develop interventions addressing the biology of aging and age-associated diseases.